Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 330 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Insights Into the Biology of Response and Resistance to MAPK Pathway... October 16, 2024 Rescued From Complete Darkness July 1, 2021 Celebrate with Us! Vaccine Rollouts Mark the Light at the End... March 8, 2021 Cancer in children and young people: how far we’ve come September 29, 2021 Load more HOT NEWS Family Brings Joy & Raises Money With Their Extravagant Christmas Light... Breast-Cancer Mom Is Living On 84 Pence As She Fights For... Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or... Trialling a new way to boost CAR T-cell therapy
